GlobeNewswire Inc.··Pmv Pharmaceuticals, Inc.PMV Pharma's Rezatapopt Shows Promise, But Cash Clock Ticks Toward 2027
PMV Pharmaceuticals reports 50% response rate for ovarian cancer drug rezatapopt, but faces funding pressure with cash runway extending only to Q2 2027.
PMVPclinical trial resultsorphan drug designation